PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005182-66

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the safety and efficacy of the 10 mg intravenous (IV) dose of tanezumab in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label tanezumab therapy.


Critère d'inclusion

  • PAIN DUE TO BONE METASTASES